Natera executive sells 3,410 shares in planned trades

Natera, Inc. executive Solomon Moshkevich, president of clinical diagnostics, reported selling a total of 3,410 shares of common stock on 2026-08-03 in multiple open-market transactions.

Rhea-AI Filing Summary

Natera, Inc. executive Solomon Moshkevich, president of clinical diagnostics, reported selling a total of 3,410 shares of common stock on 2026-08-03 in multiple open-market transactions. Per-share prices included $267.9893 and $259.9800. 410 shares were sold to satisfy tax withholding on RSU vesting under instructions intended to meet Rule 10b5-1(c) conditions, and the remaining sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.

Insider Trade Summary 10b5-1

Net Seller: 3,410 shares

Net Sell 7 txns

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Sold 3,410 shs ($906K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	410	$267.9893	$110K
Sale	Common Stock F2	300	$259.98	$78K
Sale	Common Stock F2, F3	200	$261.4875	$52K
Sale	Common Stock F2, F4	947	$263.9415	$250K
Sale	Common Stock F2, F5	192	$265.275	$51K
Sale	Common Stock F2, F6	1,233	$267.7869	$330K
Sale	Common Stock F2, F7	128	$268.6964	$34K

Holdings After Transaction: Common Stock — 129,019 shares (Direct)

Footnotes (7)

1. F1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
2. F2. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.1500 to $261.8250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6550 to $264.2400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.27 to $265.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1550 to $268.1150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.63 to $268.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 3,410 shares Tax-withholding sale: 410 shares Sale price tranche: $267.9893 per share +4 more

7 metrics

Total shares sold 3,410 shares Aggregate Natera common stock sold on 2026-08-03 by Solomon Moshkevich

Tax-withholding sale 410 shares Shares sold to satisfy tax withholding and remittance obligations on RSU vesting

Sale price tranche $267.9893 per share Per-share price for the 410-share sale on 2026-08-03

Sale price tranche $259.9800 per share Per-share price for a 300-share sale on 2026-08-03

Weighted average price example $261.4875 per share Weighted average price for a 200-share tranche sold on 2026-08-03

Rule 10b5-1 plan adoption date November 26, 2024 Adoption date of trading plan governing certain reported sales

Stock Unit Agreement grant date January 31, 2025 Grant date referenced for RSU-related tax-withholding sale

Key Terms

Rule 10b5-1 trading plan, RSUs, weighted average price, tax withholding and remittance obligations, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

RSUs financial

"in connection with the vesting of RSUs and was made pursuant"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding and remittance obligations financial

"in order to satisfy tax withholding and remittance obligations in connection"

affirmative defense conditions of Rule 10b5-1(c) regulatory

"intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Solomon Moshkevich report for Natera (NTRA) on 2026-08-03?

Solomon Moshkevich reported selling 3,410 shares of Natera common stock on 2026-08-03 in several open-market transactions, with per-share prices including $267.9893 and $259.9800, as disclosed in the Form 4 filing.

How many Natera (NTRA) shares were sold to cover RSU tax obligations?

The Form 4 shows 410 shares of Natera common stock were sold to satisfy tax withholding and remittance obligations arising from RSU vesting, under written instructions tied to a Stock Unit Agreement granted on January 31, 2025.

Were Solomon Moshkevich’s Natera (NTRA) share sales made under Rule 10b5-1 plans?

Yes. The filing affirms Rule 10b5-1 status, and footnotes state one sale followed instructions intended to satisfy Rule 10b5-1(c) and the remaining sales were effected under a Rule 10b5-1 trading plan adopted on November 26, 2024.

At what prices did Solomon Moshkevich sell Natera (NTRA) shares?

Reported per-share sale prices include $267.9893 for 410 shares and $259.9800 for 300 shares, with additional tranches at weighted average prices such as $261.4875, $263.9415, $265.2750, $267.7869, and $268.6964.

What is Solomon Moshkevich’s role at Natera (NTRA) in this Form 4?

Solomon Moshkevich is identified as an officer of Natera, serving as President, Clinical Diagnostics, and is the sole reporting person for the common stock sales disclosed in this Form 4 insider transaction report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 09:35 PM Accepted by SEC EDGAR 08/05/2026 - 09:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TEXAS 78753

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S		410(1)	D	$267.9893	132,019	D
Common Stock	08/03/2026		S		300(2)	D	$259.98	131,719	D
Common Stock	08/03/2026		S		200(2)	D	$261.4875(3)	131,519	D
Common Stock	08/03/2026		S		947(2)	D	$263.9415(4)	130,572	D
Common Stock	08/03/2026		S		192(2)	D	$265.275(5)	130,380	D
Common Stock	08/03/2026		S		1,233(2)	D	$267.7869(6)	129,147	D
Common Stock	08/03/2026		S		128(2)	D	$268.6964(7)	129,019	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

2. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.1500 to $261.8250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6550 to $264.2400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.27 to $265.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1550 to $268.1150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.63 to $268.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Tami Chen, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)